Repeated COVID-19 infection in recipients of post-living donor liver transplantation: Two real-life cases
Journal of Liver Transplantation
; 1 (no pagination), 2021.
Article
in English
| EMBASE | ID: covidwho-2300314
ABSTRACT
COVID-19 is an emerging pandemic. The course and management of the disease in the liver transplant setting may be difficult due to a long-standing immunosuppressive state. In Egypt, the only available option is living donor liver transplantation (LDLT). In our centre, we have transplanted 440 livers since 2008. In this study, we report a single-centre experience with COVID-19 infection in long-term liver transplant recipients. A total of 25 recipients (5.7 %) had COVID-19 infections since March 2020. Among these recipients, two developed COVID-19 infections twice, approximately three and two months apart, respectively.Copyright © 2021 The Author(s)
covid-19; Liver transplant; Pandemic; SARS-CoV-2; abnormal laboratory result; acute kidney failure/dt [Drug Therapy]; adult; arterial gas; article; asymptomatic infection; case report; clinical article; clinical feature; coronavirus disease 2019/di [Diagnosis]; coronavirus disease 2019/dt [Drug Therapy]; coughing; creatinine blood level; diarrhea; dyspnea; Egypt; fever; fluid therapy; graft recipient; ground glass opacity/di [Diagnosis]; hepatitis C/su [Surgery]; hospitalization; human; human cell; human tissue; hypotension; intermediate care unit; kidney function; kidney infection; length of stay; liver cirrhosis/su [Surgery]; liver transplantation; living donor; lung consolidation/di [Diagnosis]; lung infection; male; medical examination; metabolic acidosis/di [Diagnosis]; middle aged; nasopharyngeal swab; patient history of liver transplantation; polymerase chain reaction; potassium blood level; reinfection/di [Diagnosis]; respiratory tract disease; sepsis/di [Diagnosis]; sepsis/dt [Drug Therapy]; Severe acute respiratory syndrome coronavirus 2; thorax radiography; azithromycin/cb [Drug Combination]; azithromycin/dt [Drug Therapy]; azithromycin/pv [Special Situation for Pharmacovigilance]; creatinine/ec [Endogenous Compound]; cyclosporine/dt [Drug Therapy]; cyclosporine/pv [Special Situation for Pharmacovigilance]; enoxaparin/pv [Special Situation for Pharmacovigilance]; hydroxychloroquine/dt [Drug Therapy]; hydroxychloroquine/po [Oral Drug Administration]; hydroxychloroquine/pv [Special Situation for Pharmacovigilance]; imipenem/cb [Drug Combination]; imipenem/dt [Drug Therapy]; imipenem/pv [Special Situation for Pharmacovigilance]; immunosuppressive agent; mycophenolate mofetil/dt [Drug Therapy]; oseltamivir/dt [Drug Therapy]; oseltamivir/pv [Special Situation for Pharmacovigilance]; potassium/ec [Endogenous Compound]; cryptogenic cirrhosis
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Journal of Liver Transplantation
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS